← Back to patent-cliff list
KT-621
Tier C — Watch / tradeKT-621
Kymera Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：STAT6
Indications (approved)：Asthma, 肺嗜酸粒细胞增多, Atopic dermatitis, Alzheimer's disease, Sinusitis, Chronic obstructive pulmonary disease, Oesophageal disease, Peripheral nervous system disorder
Regional status
US
Phase II
2025-11-24
EU
Phase II
2025-11-24
China
-
Japan
Phase II
2025-11-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of KT-621?
Approved indications include: Asthma, 肺嗜酸粒细胞增多, Atopic dermatitis, Alzheimer's disease, Sinusitis, Chronic obstructive pulmonary disease, Oesophageal disease, Peripheral nervous system disorder.
When does the KT-621 patent expire?
No public expiry year is available for KT-621 yet; this page updates once verified.
How do I get a quote for KT-621 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22